

25 September 2017

Pathophysiology of Cardiogenic Shock & Heart Failure



เอกราช อริยะชัยพาณิชย์

Heart Failure and Transplant Cardiology

aekarach.a@chula.ac.th

Presentation at




Agenda


- Physiology of the heart
- Pathophysiology of shock
- Pathophysiology of heart failure



<http://fullpulse.weebly.com/conversation>

1. What is the heart ?
 2. What is the function of the heart ?
-






Google what is the heart

Web Images Videos News More Search tools

About 687,000,000 results (0.50 seconds)

heart
/härt/ 
noun

1. a hollow muscular organ that pumps the blood through the circulatory system by rhythmic contraction and dilation. In vertebrates there may be up to four chambers (as in humans), with two atria and two ventricles.
synonyms: informal ticker
"my heart stopped beating"

To pump the blood

Cardiac output (CO)

- The amount of blood that the heart pumps in 1 minute (L/min)
- Normal = 6 L/min

Heart rate (bpm)

Stroke volume (ml/beat)

What regulate stroke volume



What regulate stroke volume


Preload
Afterload
Contractility




What is the preload ?



Preload



Frank-Starling Mechanism



Preload

➤ A load (force/tension) that stretch the muscle before the initiation of contraction





➤ Myocardial cell length

➤ LV end diastolic volume --- LV size


➤ Pressure that stretch the heart

➤ End diastolic pressure --- LVEDP





➤ Atrial pressure




What is the afterload ?



Afterload



Afterload



Afterload in Clinical

A “load” (resistant) that the heart has to contract against


- Vascular resistant
- Systolic blood pressure
- Vaso-constriction
- etc.

What is the contractility ?





Contractility


An intrinsic property of the myocyte at a giving load



Cardiac output



What is shock?



What is shock ?

“The clinical syndrome characterize by an **inadequate global tissue perfusion.**”

- Usually have hypotension (MAP < 60 mmHg)

Initiate by **various causes**

Lead to a **vicious cycle of damages**, due to

- Cellular dysfunction → functional and structural change.
- Multiple organ failure and death.

Adapt from harrison principles of internal medicine 18th edition

HYPOTENSION ≠ SHOCK

Hypoperfusion: Lead to a **vicious cycle of damages**

Cellular

- ATP depletion
- Aerobic to anaerobic
- Abnormal membrane function
- Cell dysfunction, swelling, death
- Inflammatory response
- Hematologic response

Multiorgan involments

- Renal failure
 - Acute kidney injury
- Liver failure
 - Ischemic hepatitis, shock liver
- Respiratory distress or failure
- Cardiac depression
- DIC

S&S symptoms of hypoperfusion

Δ mental status

Tachycardia

↓ BP

↓ urine

cold skin

↑Cr

↑Lactic acid

etc





Figure 270-1 Shock-induced vicious cycle.

Initiate by various causes



NEJM 2013

Type of shock initiation and compensatory mechanism

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic shock				
Cardiogenic shock				
Distributive shock				
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock initiation and compensatory mechanism

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic shock	High preload: ↑ JVP, (+) ascites, edema, (+) crepitations			
Cardiogenic shock	Low preload: dry mucosa, low JVP, skin turgor, orthostatic hypotension			
Distributive shock				
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock initiation and compensatory mechanism

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic shock	High afterload: cold skin, pale, ↑SVR			
Cardiogenic shock	Low preload: warm skin, ↑SVR			
Distributive shock				
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock initiation and compensatory mechanism

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic shock	↓			
Cardiogenic shock		↓		
Distributive shock			↓	
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Type of shock initiation and compensatory mechanism

Type of Shock	Preload	CO	Afterload	Cause
Hypovolemic shock	↓	~↑	↑	Blood or fluid loss (internal, external)
Cardiogenic shock	↑	↓	↑	Acute MI, acute HF Arrhythmia, cardiac tamponade pulmonary emboli
Distributive shock	~↓	↑↓	↓	Septic, anaphylaxis, inflammation, toxin
Other type of shocks: Hypoadrenal, neurogenic, obstructive				

Treatment

Type of Shock	Preload	CO	Afterload
Hypovolemic shock	↓	~↑	↑
Cardiogenic shock	↑	↓	↑
Distributive shock	~↓	↑↓	↓

Reverse the cause(s)

- In a timely fashion

Support and prevent further end organ damage

- Restore perfusion, reverse the physiology

ICU:

Fluid resuscitation: Crystalloid > colloid, ~~Cardiogenic shock~~

Circulatory support: Inotrope, vasopressor medications, Devices

Ventilation support: O2 support, Mechanical Ventilator/ Endotracheal tube

Invasive monitor: Arterial line, PA catheter (Swan-Ganz), Foley cath

	Action	Usual dose	C ¹	A ²	Note
Epinephrine	α1 β1 β2	0.01-0.1mcg/kg/min 1 mg iv bolus q 3 mins	↑↑↑↑	↑↑↑	Low dose = more β. (like dobutamine) High dose = more α. (like norepi) Use: ACLS, anaphylaxis, S/E: splanchnic vasoconstrict.
Norepinephrine	α1 β1 β2	0.01-3 mcg/kg/min	↑↑↑	↑↑↑↑	Potent vasoconstriction. Moderate ↑CO. ~HR effect (reflex bradycardia from increased MAP). Use: Septic shock.
Dopamine Low Moderate High	DA α1 β1 β2 DA α1 β1 β2 DA	0.5 - 2 mcg/kg/min 2-10 mcg/kg/min 10-20 mcg/kg/min	~ ↑↑ ↑↑	↓ ↑ ↑↑↑	Precursor to norepi but less α, more β effect. Dose-dependent effects. Dose is varied pt to pt. Use: Septic shock, 2 nd -line alternative to norepinephrine.
Dobutamine	β1 β2 (α1)	2- 20 mcg/kg/min	↑↑	↓↓	Not a vasopressor. Inotrope with a vasodilation. The net effect = ↑CO + ↓SVR, may not ↓BP. Use: HF, cardiogenic.
Milrinone	PDE inh	0.375 – 0.75 mcg/kg/min	↑↑	↓↓↓	Similar to dobutamine more vasodilator, ↓PA Use: HF, cardiogenic.
Isoproterenol	β1 β2	2-10 mcg/min	↑	↓↓↓	Prominent chronotropic. Prominent vasodilation. Use: Bradycardia
Phenylephrine	α1	0.5-10 mcg/kg/min	0	↑↑↑	Pure vasoconstriction. May decrease SV.
Vasopressin	V ₁	0.04 unit/min	0	↑↑↑	Pure vasoconstriction. Use: 2 nd -line in refractory vasodilatory shock. S/E: coronary, mesenteric ischemia, skin necrosis. ↓Na and pulm vasoconstriction

Sample

A 55 yo M with hx of HTN, DM presents with “crushing” substernal CP, diaphoresis, hypotension, tachycardia and cool, clammy extremities

An 81 yo F from a nursing home presents to the ED with altered mental status. She is febrile to 39.4, hypotensive with a widened pulse pressure, tachycardic, with warm extremities

A 68 yo M with hx of HTN and DM presents to the ER with abrupt onset of diffuse abdominal pain with radiation to his low back. The pt is hypotensive, tachycardic, afebrile, with cool but dry skin

Cause of Hypovolemic Shock

- Non-hemorrhagic
 - Vomiting
 - Diarrhea
 - Neglect, environmental (dehydration)
 - Bowel obstruction, pancreatitis
 - Burns
- Hemorrhagic
 - GI bleed
 - Trauma
 - Massive hemoptysis
 - AAA rupture
 - Ectopic pregnancy, post-partum bleeding

Cause of Septic shock

Most common type of shock

Hypoperfusion + infection + 2 SIRS (systemic inflammatory response syndrome) criteria

- S&S of hypoperfusion
- Temp > 38 or < 36 C
- HR > 90
- RR > 20
- WBC > 12,000 or < 4,000
- Plus the presumed existence of infection

Cause of cardiogenic shock

Etiologies of Cardiogenic Shock or Pulmonary Edema

Acute myocardial infarction/ischemia
 LV failure
 VSR
 Papillary muscle/chordal rupture—severe MR
 Ventricular free wall rupture with subacute tamponade

Post-cardiac arrest

Post-cardiotomy

Refractory sustained tachyarrhythmias

Acute fulminant myocarditis

End-stage cardiomyopathy

Left ventricular apical ballooning

Takotsubo's cardiomyopathy

Hypertrophic cardiomyopathy with severe outflow obstruction

Aortic dissection with aortic insufficiency or tamponade

Pulmonary embolus

Severe valvular heart disease

 Critical aortic or mitral stenosis

 Acute severe aortic or MR

Toxic-metabolic

 Beta-blocker or calcium channel antagonist overdose

Other Etiologies of Cardiogenic Shock^o

RV failure due to:

 Acute myocardial infarction

 Acute coronary pulmonale



Refractory sustained bradyarrhythmias

Pericardial tamponade


Toxic/metabolic

 Severe acidosis, severe hypoxemia

Pathophysiology




Heart failure



Definition of HF

1. A syndrome caused by cardiac abnormality
2. Leads to circulatory abnormalities and neurohormonal abnormality
3. Resulting in typical symptoms of
 - Congestion
 - Poor perfusion
 - a. Common pathway from any cardiac injury
 - b. Progressive, remodeling
 - c. Vicious cycle from maladaptation






Cause of HF


Table of Contents	
Preamble	e242
1. Introduction	e245
1.1. Methodology and Evidence Review	e245
1.2. Organization of the Writing Committee	e245
1.3. Document Review and Approval	e245
1.4. Scope of This Guideline With Reference to Other Relevant Guidelines or Statements	e245
2. Definition of HF	e246
2.1. HF With Reduced EF (HFrEF)	e247
2.2. HF With Preserved EF (HFpEF)	e247
3. HF Classifications	e247
4. Epidemiology	e248
4.1. Mortality	e248
4.2. Hospitalizations	e248
4.3. Asymptomatic LV Dysfunction	e248
4.4. Health-Related Quality of Life and Functional Status	e249
4.5. Economic Burden of HF	e249
4.6. Important Risk Factors for HF (Hypertension, Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease)	e249
5. Cardiac Structural Abnormalities and Other Causes of HF	e249
5.1. Dilated Cardiomyopathies	e249
5.1.1. Definition and Classification of Dilated Cardiomyopathies	e249
5.1.2. Epidemiology and Natural History of DCM	e250
5.2. Familial Cardiomyopathies	e250
5.3. Endocrine and Metabolic Causes of Cardiomyopathy	e250
5.3.1. Obesity	e250
5.3.2. Diabetic Cardiomyopathy	e250
5.3.3. Thyroid Disease	e250
5.3.4. Acromegaly and Growth Hormone Deficiency	e250
5.4. Toxic Cardiomyopathy	e251
5.4.1. Alcoholic Cardiomyopathy	e251
5.4.2. Cocaine Cardiomyopathy	e251
5.4.3. Cardiotoxicity Related to Cancer Therapies	e251
5.4.4. Other Myocardial Toxins and Nutritional Causes of Cardiomyopathy	e251
5.5. Tachycardia-Induced Cardiomyopathy	e251
5.6. Myocarditis and Cardiomyopathies Due to Inflammation	e251
5.6.1. Myocarditis	e251
5.6.2. Acquired Immunodeficiency Syndrome	e252
5.6.3. Chagas Disease	e252
5.7. Inflammation-Induced Cardiomyopathy: Noninfectious Causes	e252
5.7.1. Hypersensitivity Myocarditis	e252
5.7.2. Rheumatological/Connective Tissue Disorders	e252
5.8. Peripartum Cardiomyopathy	e252
5.9. Cardiomyopathy Caused by Iron Overload	e252
5.10. Amyloidosis	e252
5.11. Cardiac Sarcoidosis	e253
5.12. Stress (Takotsubo) Cardiomyopathy	e253
6. Initial and Serial Evaluation of the HF Patient	e253
6.1. Clinical Evaluation	e253
6.1.1. History and Physical Examination: Recommendations	e253
6.1.2. Risk Scoring: Recommendation	e253
6.2. Diagnostic Tests: Recommendations	e253
6.3. Biomarkers: Recommendations	e255
6.3.1. Natriuretic Peptides: BNP or NP-proBNP	e256
6.3.2. Biomarkers of Myocardial Injury: Cardiac Troponin T or I	e256
6.3.3. Other Emerging Biomarkers	e256
6.4. Noninvasive Cardiac Imaging: Recommendations	e256
6.5. Invasive Evaluation: Recommendations	e258
6.5.1. Right-Heart Catheterization	e259
6.5.2. Left-Heart Catheterization	e259
6.5.3. Endomyocardial Biopsy	e260
7. Treatment of Stages A to D	e260
7.1. Stage A: Recommendations	e260
7.1.1. Recognition and Treatment of Elevated Blood Pressure	e260
7.1.2. Treatment of Dyslipidemia and Vascular Risk	e260
7.1.3. Obesity and Diabetes Mellitus	e260
7.1.4. Recognition and Control of Other Conditions That May Lead to HF	e261
7.2. Stage B: Recommendations	e261
7.2.1. Management Strategies for Stage B	e262
7.3. Stage C	e262

Circulation. 2013;128:e240-e327.

Pathophysiology Remodeling







The result of Adverse remodeling

TABLE 25-2 Overview of Left Ventricular Remodeling

Alterations in Myocyte Biology

Excitation-contraction coupling
Myosin heavy chain (fetal) gene expression
Beta-adrenergic desensitization
Hypertrophy
Myocytolysis
Cytoskeletal proteins


Myocardial Changes

Myocyte loss
Necrosis
Apoptosis
Autophagy
Alterations in extracellular matrix
Matrix degradation
Myocardial fibrosis

Alterations in Left Ventricular Chamber Geometry

LV dilation
Increased LV sphericity
LV wall thinning
Mitral valve incompetence

Stage of HF



Classification of HF

<u>Chronicity</u> Acute Chronic	<u>Stage</u> A, B, C, D	<u>EF</u> rEF (< 40%) pEF (≥ 50%) mrEF (40-50)	<u>Hemodynamic profile</u> Wet - Dry Cold - warm
<u>NYHA fn class</u> I, II, III, IV	<u>Etiology</u> Ischemic cause Non-ischemic cause	<u>involvement</u> LV RV Both	<u>phenotype</u> Dilated Hypertrophic Restrictive
Endo / myo / epi	Backward / Forward failure	Low / High output	Systolic / diastolic failure

S&S of HF


Non-specific

Dyspnea from increased breathing drive

- Reduction in exercise capacity (NYHA II-IV)
- Orthopnea, PND

Wt gain, leg swollen, fatigue, early satiety, N/V, confusion

Apical shift, S3, S4, ↑ JVP, (+) HJR, crepitations, ascites, edema



Treatment

Treat the cause

Self-care

- weight monitor, ↓ salt intake

Diuretics to control volume status

Treatment: Chronic

Chronic

- Betablocker
- ACE / ARB
- Aldosterone blocker - spironolactone
- Angiotensin receptor, neprilysin inhibitor(ARNI) - Valsartan/sacubitril
- Other meds: Ivabradine, HDZ, ISDN, digoxin
- CRT - Cardiac resynchronize therapy (special pacemaker)
- ICD - Implantable cardioverter Defibrillator

Acute

Aggressive diuresis, vasodilator, inotrope

End-staged HF

- Heart transplant, mechanical circulatory support, palliative care

Advances in Heart Failure

The “Modern” View of Heart Failure How Did We Get Here?

Arnold M. Katz, MD

Circ Heart Fail.2008;1:63-71

Thank you

Aekarach.a@chula.ac.th

